Re-treatment with radium-223: first experience from an international, open-label, phase I/II study in patients with castration-resistant prostate cancer and bone metastases
Keyword(s):
Phase I
◽
2014 ◽
Vol 32
(15_suppl)
◽
pp. TPS5103-TPS5103
◽
2020 ◽
Vol 18
(5)
◽
pp. 416-422
◽
2010 ◽
Vol 28
(15_suppl)
◽
pp. 4678-4678
◽